spectraldx产品代理
spectraldx产品代理
众所周知，内毒素是败血症的诱因。Spectral 对其主导产品 PMX（Toraymyxin™ PMX-20R）进行了 III 期临床试验，用于治疗感染性休克和内毒素血症患者（通过公司的内毒素活性测定法 (EAA™) 测量）。
PMX 是一种治疗性血液灌流装置，可从血液中去除循环内毒素。EUPHRATES 关键试验（评估多粘菌素 B 血液灌流在接受内毒素血症和感染性休克治疗的成人的随机对照试验中的使用）表明，当 PMX 应用于内毒素活性 (EA) 基线值在 0.6 和 0.9 之间的感染性休克患者时，降低死亡率并改善器官功能障碍。
EAA™ Endotoxin Activity Assay
Toraymyxin™ PMX
Reagents
SAMI
Spectral’s vision is to provide a personalized approach that will enable vastly improve outcomes for patients with septic shock by combining a targeted diagnostic test and therapy.
It is widely known that endotoxin is a trigger of sepsis. Spectral has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin™ PMX-20R), for the treatment of patients with septic shock and endotoxemia (measured by the Company’s Endotoxin Activity Assay (EAA™)).
PMX is a therapeutic hemoperfusion device that removes circulating endotoxin from the bloodstream. The EUPHRATES pivotal trial, (Evaluating Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock) showed that PMX, when applied to septic shock patients with a baseline value of endoxotin acitivity (EA) between 0.6 and 0.9, reduces mortality and improves organ dysfunction.
EAA™ and PMX are both Health Canada licensed and commercially available in Canada.
Spectral strives to exceed the highest ethical, financial and scientific standards in all our operations and activities. By maintaining excellent relationships within the clinical community, as well as with customers and business partners, Spectral aims to win the battle against sepsis mortality with the first ever theranostic – EAA™ and Toraymyxin.
